Nanotech opens door to exciting new ocular therapies

Nanotech opens door to exciting new ocular therapies

Nanotechnology is all set to make a positive impact on many aspects of ophthalmology including drug and gene therapy delivery methods, delegates attending the World Ophthalmology Congress 2012 were told at a special session on new technology in ophthalmology.

'This is new and exciting technology which allows us to manipulate matter at the smallest scale. We will be able to make technology that looks at harnessing some of the processes in living systems to generate energy to power devices that could be implanted inside bodies and allows us to improve human biological systems at the molecular level,' said Carlo Montemagno in a broad overview of the coming nanotechnology revolution.

Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...